[ad_1]
The University of Oxford had to stop clinical trials last Sunday after a subject contracted an unexplained illness in the UK. The AstraZeneca coronary vaccine is in the final stages of testing. The vaccine is being tested in Phase 3 in the United States and in Phases 2 and 3 in the United Kingdom, Brazil, and South Africa.
Also Read: Coronary Vaccine Trial Stops After Possible Serious Side Effects
The company did not provide further information on the type of symptoms the person conducting the test had experienced, but an AstraZeneca spokesperson described the breakdown as a “standard routine that should be followed when a potentially unexplained illness is detected in a test.”
– Safe to continue
Now, however, the hiatus is over, without the drug company wanting to specify when testing will continue.
“British health authorities have completed their investigations and concluded that it is safe to continue clinical trials,” AstraZeneca writes in a press release.
ALWAYS UPDATED: Latest news on corona pandemic in Nettavisen news studio
The company has also come out and said that what happened recently was not in itself something dramatic.
– Worldwide, 18,000 people have received vaccines as part of the tests. In large clinical trials like this one, some participants are expected to be deficient, and each case must be carefully scrutinized to ensure safety, the company writes in a statement, according to CNN.
Agreement with the Norwegian authorities
In mid-August, Health Minister Bent Høie (H) said that the EU Commission had reached an agreement with AstraZeneca on the so-called Oxford vaccine, and that Norway is part of the cooperation through the EEA agreement.
Read also: Høie: – Good news about vaccines arrived on Friday
– We support Norway in the fight against the coronavirus, the president of the European Commission, Ursula von der Leyen, wrote on Twitter.
The Oxford vaccine has been in testing since April and is one of the longest-running vaccine candidates. Health director Bjørn Guldvog has already commented when the Norwegian population can access the vaccine.
[ad_2]
